Skip to main content
Top

Cancer Microenvironment

Issue 2-3/2018

Content (6 Articles)

Review

Skewed Signaling through the Receptor for Advanced Glycation End-Products Alters the Proinflammatory Profile of Tumor-Associated Macrophages

Armando Rojas, Paulina Araya, Jacqueline Romero, Fernando Delgado-López, Ileana Gonzalez, Carolina Añazco, Ramon Perez-Castro

Original Article

Tumor-Associated T-Lymphocytes and Macrophages are Decreased in Endometrioid Endometrial Carcinoma with MELF-Pattern Stromal Changes

Dmitry Aleksandrovich Zinovkin, Md Zahidul Islam Pranjol, Il’ya Andreevich Bilsky, Valeriya Alexandrovna Zmushko

Original Article

Ascites IL-10 Promotes Ovarian Cancer Cell Migration

Denis Lane, Isabelle Matte, Perrine Garde-Granger, Paul Bessette, Alain Piché

Original Article

Cerebrospinal Fluid Hyaluronan and Neurofibromatosis Type 2

Prasanth S. Ariyannur, Narendranath Vikkath, Ashok B. Pillai

Open Access Original Article

T-Cell Clustering in Neoplastic Follicles of Follicular Lymphoma

Patrick Schnotalle, Karoline Koch, Rex K. H. Au-Yeung, Sarah Reinke, Karsten Winter, Markus Loeffler, Ulf-Dietrich Braumann, Wolfram Klapper

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine